Jack O'Brien is the finance editor at HealthLeaders, a Simplify Compliance brand.
The Johnson & Johnson Medical Devices Companies survey is the latest indication of what issues healthcare leaders are focused on addressing.
Between 2011 and 2015, rebates for brand-name prescription drugs still increased $2 billion.
A clinical protocol is proving that it can make a positive impact in the operating room and on the bottom line.
The report expects employers and health plans to exert more influence in demanding market power going forward.
The study predicts that the total cost of care associated with osteoporotic fractures will be $95 billion in 2040.
The heightened risk of a recession next year ranks among the major challenges facing the sector.
The two Golden State providers announced the affiliation Thursday but did not specify an expected closure date.
The West Virginia-based provider has struggled with mounting losses in recent years as well as the lack of an interested buyer.
The move comes more than a week after the state of Oklahoma won its landmark lawsuit against Johnson & Johnson for its role in the opioid crisis.
A Moody's report highlighted the similarities between UnitedHealth's disputes with Envision Healthcare and Team Health.